Literature DB >> 11174412

Childhood bullous pemphigoid developed after the first vaccination.

C Baykal1, G Okan, R Sarica.   

Abstract

Bullous pemphigoid (BP) typically affects the elderly. There are at least 40 reported cases of BP in childhood, 10 reported cases at 1 year of age or younger. The antigen of this autoimmune disease is localized to the hemidesmosome. Neoplasia, recurrent trauma, some systemic diseases, and psoriasis were previously reported as possible triggering factors of bullous pemphigoid in some cases. In the last 5 years, 10 adult and 2 infantile BP cases with a close relation of vaccination have been reported. Anti-influenza vaccine, tetanus toxoid booster, and tetracoq vaccine were the possible causes of these cases. We report herein a 3.5-month-old BP case in whom the lesions developed 24 hours after the first tetracoq vaccine. We suggest that vaccination may be the triggering factor of BP of any age by stimulating the immune system with an unexplained mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174412     DOI: 10.1067/mjd.2001.103034

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid.

Authors:  Natasha Walmsley; Philip Hampton
Journal:  J Dermatol Case Rep       Date:  2011-12-12

2.  Extrahepatic manifestations of acute hepatitis B virus infection.

Authors:  Matthew R Kappus; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-02

Review 3.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

Review 4.  Spontaneous and antiviral-induced cutaneous lesions in chronic hepatitis B virus infection.

Authors:  Ioana Grigorescu; Dan Lucian Dumitrascu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

5.  Recalcitrant infantile bullous pemphigoid successfully treated with cyclosporine.

Authors:  Efrat Bar-Ilan; Andrea Izabella Gál; Klára Veres; Anna Solti; Petra Ágnes Ferge; Tímea Dimény; Norbert Kiss; Zsuzsanna Szalai
Journal:  JAAD Case Rep       Date:  2022-09-13

6.  Two infants with blistering rashes originating on acral sites as a presenting sign of infantile bullous pemphigoid.

Authors:  Brent Folsom; Tom Raisanen; Milad Eshaq
Journal:  JAAD Case Rep       Date:  2020-04-18

Review 7.  Clinical relevance of autoantibodies in patients with autoimmune bullous dermatosis.

Authors:  Lilla Mihályi; Mária Kiss; Attila Dobozy; Lajos Kemény; Sándor Husz
Journal:  Clin Dev Immunol       Date:  2012-12-24

8.  Bullous pemphigoid in infants: characteristics, diagnosis and treatment.

Authors:  Agnes Schwieger-Briel; Cornelia Moellmann; Birgit Mattulat; Franziska Schauer; Dimitra Kiritsi; Enno Schmidt; Cassian Sitaru; Hagen Ott; Johannes S Kern
Journal:  Orphanet J Rare Dis       Date:  2014-12-10       Impact factor: 4.123

Review 9.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10

10.  Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.

Authors:  A Català; C Muñoz-Santos; C Galván-Casas; M Roncero Riesco; D Revilla Nebreda; A Solá-Truyols; P Giavedoni; M Llamas-Velasco; C González-Cruz; X Cubiró; R Ruíz-Villaverde; S Gómez-Armayones; M P Gil Mateo; D Pesqué; O Marcantonio; D Fernández-Nieto; J Romaní; N Iglesias Pena; L Carnero Gonzalez; J Tercedor-Sanchez; G Carretero; T Masat-Ticó; P Rodríguez-Jiménez; A M Gimenez-Arnau; M Utrera-Busquets; E Vargas Laguna; A G Angulo Menéndez; E San Juan Lasser; M Iglesias-Sancho; L Alonso Naranjo; I Hiltun; E Cutillas Marco; I Polimon Olabarrieta; S Marinero Escobedo; X García-Navarro; M J Calderón Gutiérrez; G Baeza-Hernández; L Bou Camps; T Toledo-Pastrana; A Guilabert
Journal:  Br J Dermatol       Date:  2021-09-21       Impact factor: 11.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.